Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen

Climacteric

Volumn 11, Issue 3, 2008, Pages 252-257

  Kesim, M D ^a   Aydin, Y ^a,b   Atis, A ^a   Mandiraci, G ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Breast; Cancer; Endometrium; High density lipoprotein; Levonorgestrel releasing intrauterine system; Low density lipoprotein; Tamoxifen; Triglyceride

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLEEDING; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTALGIA; POSTMENOPAUSE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CONTRACEPTIVE AGENTS, FEMALE; DRUG INTERACTIONS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LIPIDS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; POLYPS; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; UTERINE DISEASES;

EID: 48249094268     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802163168     Document Type: Article

References (27)

1. Hammond CB, Soules MR. Endocine aspects of the endometrium. In Buchsbaum HJ, Sciarra JJ, eds. Gynecology and Obstetrics. Vol 14. Philadelphia: Harper & Row, 1984:1-5
2. Daniel Y, Inbar M, Bar-Am A, et al. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996;65:1083-9
3. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-9
4. Baum M, the Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Br J Cancer 1988;57:608-11
5. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92
6. Gottardis MM, Robinson SP, Satyawaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-15
7. Neven P. Local levonorgestrel to prevent tamoxifen-related endometrial lesions. Lancet 2000;356:1698-9
8. Bergman L, Beelen MRL, Gallee MPW, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7
9. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Safety 2000;22:1-11
10. Juneja M, Jose R, Kekre AN, Viswanathan F, Seshadri L. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynaecol Obstet 2002;76:279-84
11. Gardner FJE, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356:1711-17
12. Ballard P, Turnbull L, Richmond I, Tetlow R. The effect of a levonorgestrol intrauterine system on the endometrium of patients receiving long-term tamoxifen treatment for breast cancer. Br J Obstet Gynaecol 1998;105(Suppl 17):abstr 299
13. Speroff L. Amenorrhea. In Glass RH, Kase NG, Speroff L, eds. Clinical Gynecologic Endocrinology and Infertility, 6th edn. Vol 11. Baltimore: Williams & Wilkins, 1996: 421-86
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-67
15. Van Leeuwen FE, Bernaadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52
16. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A:1464-76
17. Sasco AJ, Chaplain G, Amoros E, Saez S. Endometrial cancer following breast cancer; effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;7:9-13
18. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62
19. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-10
20. Martin L, Middleton E. Prolonged estrogenic and mitogenic activity of tamoxifen in ovariectomized mouse. J Endocrinol 1978;78:125-9
21. De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991;36:127-30
22. Powles TJ, Bourne T, Athanasiou S, et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998;78:272-5
23. Pakarinen P, Toivonen J, Luukkainen T. Therapeutic use of the LNG-IUS and counseling. Semin Reprod Med 2001;19:365-72
24. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-63
25. Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000;15(Suppl 3):162-72
26. Raudoskoski T, Tapanainen J, Tomas E. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral estrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002;109:136-44
27. Wollter-Svensson LO, Stadberg E, Anderson K, et al. Intrauterine administration of levonorgestrel in two low doses in HRT randomised clinical trial during one year; effects on lipid and lipoprotein metabolism. Maturitas 1995;22:199-205